Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Robert Renninger currently holds 300,000 shares of Athira Pharma, Inc. (ATHA), valued at approximately $0. This represents their equity stake as Chief Financial Officer.
Based on SEC Form 4 filings, Robert Renninger has been a net seller of ATHA stock. They have purchased $0 and sold $7.7K worth of shares.
Robert Renninger's most recent insider trade was on Apr 9, 2026, when they sold 300,000 shares at $0.00 per share.
Robert Renninger serves as Chief Financial Officer at Athira Pharma, Inc. (ATHA). They have executed 14 insider transactions totaling $7.7K over their tenure at the company.
Robert Renninger holds the position of Chief Financial Officer at Athira Pharma, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 2 years and currently hold a stake valued at $0.
Robert Renninger has shown a selling trading pattern, with $0 in total purchases and $7.7K in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Robert Renninger was on Mar 4, 2026, when they sold $4.9K worth of LONA shares. This transaction involved 906 shares at $5.37 per share.
Robert Renninger currently owns 300,000 shares of Athira Pharma, Inc. (ATHA), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Robert Renninger's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Robert Renninger has 14 Form 4 filings on record as an insider at Athira Pharma, Inc..
Set alerts for Robert Renninger and 40,000+ other insiders.